Frontage’s Bioanalytical team has partnered with Eisai and Biogen to support the PK and PD biomarker bioanalysis of lecanemab (BAN2401) in their investigational global phase 3 study in the U.S. and China. Eisai and Biogen recently acheived favorable results of the lecanemab (BAN2401) Clarity AD study.

Lecanemab is an experimental drug being jointly developed by Biogen and Eisai that’s currently in clinical trials for the treatment of Alzheimer’s disease.
 
The Frontage team developed and validated the LC-MS-based PK method in 2010 and provided bioanalytical support to this program from Phase 1 to the late phase trial. Frontage also provided biomarker analysis (p-Tau181, NfL, and GFAP) for the Phase 3 study, meeting aggressive timelines of data lock. 
 
“Here at Frontage, we also celebrated this news because it’s a powerful reminder of the reason we are in this field–to work towards combating disease and positively improving the lives of others. We are very proud to have worked closely with our Eisai partners to support the bioanalysis of lecanemab (BAN2401) in this large global phase 3 study. We are extremely proud to be a part of the team and hope to contribute to the unmet medical needs of patients with Alzheimer’s disease,” said John Lin, Frontage’s EVP and Global Head, Bioanalytical and Biologics Services.